12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Isavuconazole regulatory update

Basilea and Astellas said FDA granted Orphan Drug designation to isavuconazole to treat invasive aspergillosis. The broad spectrum water-soluble azole antifungal is in the Phase III VITAL trial to treat aspergillosis in...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >